Litfulo(Ritlecitinib Tosylate)
PFE
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Pfizer Inc.
$5.1M
Medicare cost, 2024
$5.1M
Medicare cost, 2024
Medicare drug plans spent $5.1 million on Litfulo (ritlecitinib tosylate) in 2024, for 1,155 prescriptions and refills filled by 274 patients. Spending rose 2193% from 2023 to 2024. At about $4,441 per prescription it is a high-cost drug. California accounts for the most spending ($438,466, 9% of the total).
Medicare cost, 2024
$5.1M
+2192.5% from 2023
Prescriptions
1,155
$4,441.02 per claim
Patients
274
268 prescribers
Total spending, 2024
$5.1M
$18,720.36 per patient
Questions and answers
How much does Medicare spend on Litfulo?
Medicare prescription drug plans paid $5.1M for Litfulo in 2024, for 1,155 prescriptions and refills to 274 patients (up 2192.5% from 2023). The average cost per claim was $4,441.02.
Which state spends the most on Litfulo?
California had the highest Medicare cost for Litfulo in 2024: $438K for 104 claims, followed by Florida ($422K).
Who prescribes Litfulo the most?
Vaughan C Graves, dermatology in Phila, PA, had the highest Medicare cost for Litfulo in 2024: 34 claims costing $126K.
Who makes Litfulo?
Litfulo is made by Pfizer Inc. (PFE), listed in the Medicare spending data as Pfizer US Pharm.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Litfulo was $5.1M in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Litfulo, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Vaughan C Graves Phila, PA | Dermatology | 34 | Under 11 | $126K |
| Joel E Perdomo Slidell, LA | General Practice | 27 | Under 11 | $102K |
| Teerawit Supakorndej Mill Creek, WA | Dermatology | 17 | Under 11 | $68K |
| Polina V Rzepka Twinsburg, OH | Dermatology | 14 | Under 11 | $56K |
| Kevin McMullen Missoula, MT | Dermatology | 14 | Under 11 | $56K |
| Catherine B Marcum Lakeland, FL | Dermatology | 14 | Under 11 | $54K |
| Michael J Spezia Saint Louis, MO | Family Practice | 14 | Under 11 | $53K |
| Stephanie Gonzales Albuquerque, NM | Physician Assistant | 13 | Under 11 | $53K |
| Brian L Hunter Harold, KY | Physician Assistant | 13 | Under 11 | $51K |
| Mona Olive Athens, AL | Nurse Practitioner | 13 | Under 11 | $51K |
| Jeremy S Davidson Asheville, NC | Physician Assistant | 13 | Under 11 | $51K |
| Darin T Smith Tooele, UT | Physician Assistant | 12 | Under 11 | $49K |
| Jack P Murphy La Place, LA | Dermatology | 12 | Under 11 | $48K |
| Malik C Spady Covington, LA | Rheumatology | 13 | Under 11 | $47K |
| Jessica Rodriguez Palm City, FL | Nurse Practitioner | 12 | Under 11 | $47K |
| Kristina M Dela Rosa San Diego, CA | Dermatology | 12 | Under 11 | $47K |
| Dylan Irish Mesa, AZ | Physician Assistant | 12 | Under 11 | $45K |
| Gary B Klein Valencia, CA | Dermatology | 11 | Under 11 | $44K |
| Susan Decoste Weymouth, MA | Dermatology | 12 | Under 11 | $43K |
| Anthony E Oro Stanford, CA | Dermatology | 11 | Under 11 | $43K |
| Francisco Flores Miramar, FL | Dermatology | 11 | Under 11 | $43K |
| Kristina Campton Tarrytown, NY | Dermatology | 11 | Under 11 | $43K |
| Michael Goldenberg Ashland, KY | Student in an Organized Health Care Education/Training Program | 11 | Under 11 | $43K |
| James E Cooksey Meridian, MS | Nurse Practitioner | 11 | Under 11 | $42K |
| Brian R Sperber Colorado Springs, CO | Dermatology | 11 | Under 11 | $42K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2023 | 25 | 48 | 26 | $224K |
| 2024 | 268 | 1,155 | 274 | $5.1M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Pfizer US Pharm | 1,155 | $5.1M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 1,963 side-effect reports named ritlecitinib tosylate, the active ingredient of Litfulo (reports from 2019 on). 398 of them (20.3%) were serious, 3 named a death and 106 named a hospital stay. The reactions named most often were drug ineffective, therapeutic product effect incomplete and condition aggravated. 1,962 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
1,963
771 in 2025 (+6.8% from 2024)
Serious
20.3%
398 reports
Deaths named
3
0.2% of reports
Hospital stays
106
5.4% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Litfulo?
1,963 reports from 2019 through September 2026 named ritlecitinib tosylate, the active ingredient of Litfulo. 398 of them (20.3%) were serious, 3 named a death and 106 named a hospital stay.
What are the most reported side effects of Litfulo?
346 reports named drug ineffective, the reaction named most often, followed by therapeutic product effect incomplete (135) and condition aggravated (120). In the last 5 years the reaction named most often was drug ineffective (346 reports). A report can name several reactions.
How many side-effect reports named Litfulo in 2025?
771 reports were received in 2025 (+6.8% from 2024). 2026 so far: 311 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Litfulo caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Litfulo caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
PFE·PFE drug pipeline - Drug approvals · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (ritlecitinib tosylate) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.